Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer (Q63320180)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer |
clinical trial |
Statements
An Open-label, Single-arm, Multicenter, Phase II Study to Assess the Efficacy and Safety of Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule) as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer (English)
0 references
December 2011
0 references
April 2014
0 references
30
0 references
18 year
0 references
75 year
0 references